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1. INTRODUCTION {#pai12749-sec-0005}
===============

Systemic corticosteroid treatment has not been found effective for acute treatment or secondary prevention of asthma in young wheezing children overall.[1](#pai12749-bib-0001){ref-type="ref"}, [2](#pai12749-bib-0002){ref-type="ref"}, [3](#pai12749-bib-0003){ref-type="ref"}, [4](#pai12749-bib-0004){ref-type="ref"} The limitation of prior studies has been the lack of subgroup analyses that might identify responsive children.[5](#pai12749-bib-0005){ref-type="ref"} Rhinovirus‐induced wheezing is strongly associated with recurrent wheezing and asthma up to age 13 years.[6](#pai12749-bib-0006){ref-type="ref"}, [7](#pai12749-bib-0007){ref-type="ref"} We have previously shown in two randomized controlled trials (RCTs) in first‐time wheezing children (using both post hoc [8](#pai12749-bib-0008){ref-type="ref"} and prospective designs [9](#pai12749-bib-0009){ref-type="ref"}) that a 3‐day course of oral corticosteroid (OCS) may reduce the risk of recurrent wheezing, especially in children with high rhinovirus genome load.

Previously, using a design of RCT, the effect of OCS treatment on the wheezing recurrence in rhinovirus‐affected first‐time wheezing children has only been investigated up to 12 months.[9](#pai12749-bib-0009){ref-type="ref"} In the current analysis, our aim was to investigate the need for initiation of regular asthma control medication in the 4‐year follow‐up. Based on our previous findings,[8](#pai12749-bib-0008){ref-type="ref"}, [9](#pai12749-bib-0009){ref-type="ref"} we hypothesized that in children with high rhinovirus genome load, the effect of OCS is likely to last beyond 12 months by reducing the need for initiation of long‐term asthma control medication.

2. METHODS {#pai12749-sec-0006}
==========

Vinku2, a randomized, placebo‐controlled trial ("vinku" means wheeze in Finnish) prospectively investigated the long‐term effectiveness of short course of oral prednisolone (Prednisolon^®^, Leiras Takeda, Helsinki, Finland; during the first rhinovirus‐induced wheezing episode, first dose 2 mg/kg, then 2 mg/kg/d in 2 doses for 3 days, maximum 60 mg/d, given as minced 5 mg tablets) until the age of five.[9](#pai12749-bib-0009){ref-type="ref"} Inclusion criteria were age 3‐23 months, delivery at ≥36 gestational weeks, first acute wheezing episode (parental report and confirmed from medical records), and nasopharyngeal aspirate positive for rhinovirus by PCR. Exclusion criteria were a chronic non‐atopic illness, previous systemic or inhaled corticosteroid treatment (ICS), or a need for intensive care unit treatment.[9](#pai12749-bib-0009){ref-type="ref"} The study was approved by the Ethics Committee of the Turku University Hospital and was commenced only after obtaining written informed consent from the guardians.

2.1. Study protocol {#pai12749-sec-0007}
-------------------

At study entry, patients were examined by study physician and blood samples and nasopharyngeal aspirate were taken. Children were re‐examined by study physician 2 weeks, 2 months, 12 months, and 4 years after the first wheezing episode. Parents were interviewed by study physician using standardized questionnaire at study entry and 12‐month and 4‐year follow‐ups. The electronic patient charts were reviewed regarding asthma medications, therapy adherence, and asthma symptoms for the full follow‐up period. The randomization protocol was described earlier.[9](#pai12749-bib-0009){ref-type="ref"} The trial was double‐blinded until the 12‐month follow‐up (ClinicalTrials.gov, NCT00731575).

2.2. Outcome {#pai12749-sec-0008}
------------

The primary outcome was the time to initiation of asthma control medication until the age of 5 years. The initiation of the medication was based on the 2007 National Asthma Education and Prevention Program (NAEPP) guidelines for the diagnosis of asthma in children aged \<5 years.[10](#pai12749-bib-0010){ref-type="ref"} The need for asthma control medication was defined as ≥4 wheezing episodes (≥1 diagnosed by a physician) within a year that lasted \>1 day and affected sleep, in addition to one major risk factor (physician diagnosed atopic eczema, aeroallergen sensitization, or parental history of asthma) or two minor risk factors (wheezing apart from colds, blood eosinophil count (B‐eos) ≥0.40×10^9^/L or food sensitization) and/or prolonged symptoms lasting \>4 weeks and requiring symptomatic treatment \>2 days per week, and/or two exacerbations requiring systemic corticosteroids within 6 months.[10](#pai12749-bib-0010){ref-type="ref"} In some children, asthma control medication was started after the third acute wheezing episode according to the Finnish guidelines.[11](#pai12749-bib-0011){ref-type="ref"} The interaction analysis included the effect of rhinovirus genome load (ie, copy number) on the effectiveness of prednisolone vs placebo on the main outcome.

2.3. Laboratory methods {#pai12749-sec-0009}
-----------------------

An in‐house PCR test was used for detecting rhinovirus species A, B, and C, enteroviruses, and respiratory syncytial virus (RSV) A and B from nasopharyngeal aspirate.[12](#pai12749-bib-0012){ref-type="ref"} In addition, multiplex PCR (Seeplex RV12 ACE Detection, Seegene, Seoul, Korea) was used for detecting rhinovirus, RSV A and B, adenovirus, coronavirus 229E, NL63, and HKU1, human bocavirus, human metapneumovirus, influenza A and B, and parainfluenza virus 1‐3 at the Department of Virology, University of Turku.[12](#pai12749-bib-0012){ref-type="ref"} Both an in‐house and a commercial PCR tests were used, because according to our experience, the sensitivity of the tests, especially concerning on detection of rhinovirus, differs. Rhinovirus or RSV detected by either in‐house or multiplex PCR was defined as positive. Human bocavirus was analyzed using PCR and serology.[13](#pai12749-bib-0013){ref-type="ref"} B‐eos and total and allergen‐specific serum immunoglobulin E (IgE) levels were analyzed using the routine diagnostic procedures of the Central Laboratory of Turku University Hospital. Sensitization was defined as IgE antibodies to any food or aeroallergens (Phadiatop Combi^®^; Phadia, Uppsala, Sweden, cutoff level ≥0.35 kU/L), studied in the Central Laboratory of Turku University Hospital.[14](#pai12749-bib-0014){ref-type="ref"} Serum 25‐hydroxyvitamin D (25(OH)D) measurements were made by means of liquid chromatography‐tandem mass spectrometry at Massachusetts General Hospital (Boston, MA, USA). The laboratory methods are earlier described in detail.[9](#pai12749-bib-0009){ref-type="ref"}, [12](#pai12749-bib-0012){ref-type="ref"}

2.4. Statistics {#pai12749-sec-0010}
---------------

The original power analysis was performed for 12‐month, not 4‐year, follow‐up.[9](#pai12749-bib-0009){ref-type="ref"} Baseline differences in patient characteristics between treatment groups were analyzed using *t* test (age), Mann‐Whitney *U* test (B‐eos, total IgE, 25(OH)D, rhinovirus genome load, duration of breast feeding, and delay in starting the study drug), chi‐square test (sex, any sensitization, eczema, parental allergic rhinitis, paternal smoking, pet ownership, and coinfection), or Fisher exact test (counts \<5; admission to the ward, atopic eczema, parental asthma, maternal smoking, and virus etiology). The Cox model was used for risk of the primary outcome. It included the main effects of dichotomized rhinovirus genome load and intervention group and the interaction effect of rhinovirus genome load by intervention group. The Cox model included no covariates, as no significant differences in patient characteristics were found. Survival times were censored at the age of 5 years if the event did not occur earlier. The cutoff level for rhinovirus genome load was identified by testing different copy number levels. The threshold was selected by considering significant *P‐*value for rhinovirus load vs group interaction effect similar to our previous report.[9](#pai12749-bib-0009){ref-type="ref"} IBM SPSS version 22 (SPSS Inc, Chicago, Ill, USA) was used for statistics.

3. RESULTS {#pai12749-sec-0011}
==========

3.1. Study cohort {#pai12749-sec-0012}
-----------------

A total of 79 children were randomized to receive prednisolone or placebo during their first acute wheezing episode. During the follow‐up period, 10 children were excluded from the analysis due to insufficient follow‐up time (dropouts), nine due to insufficient data about rhinovirus genome load, and one due to initiation of ICS for another reason (Figure [1](#pai12749-fig-0001){ref-type="fig"}). Finally, 59 (75%) children were analyzed (inpatient:outpatient, 80%:20%). The excluded patients did not differ from the included patients according to age, sex, atopic characteristics, viral etiology, or any other asthma‐related factors listed in Table [1](#pai12749-tbl-0001){ref-type="table"} (Table [S1](#pai12749-sup-0001){ref-type="supplementary-material"}).

![Study flowchart](PAI-28-557-g001){#pai12749-fig-0001}

###### 

Patient characteristics at study entry

  Variable                                                                    Prednisolone (n=29)   Placebo (n=30)
  --------------------------------------------------------------------------- --------------------- --------------------
  Age, months                                                                 13 (6.9)              13 (5.2)
  Male sex, no. (%)                                                           23 (79)               23 (77)
  Admission to the ward, no. (%)                                              25 (86)               22 (73)
  Any sensitization, no. (%)                                                  7/28 (25)             9/29 (31)
  B‐eos, ×10^9^/L                                                             0.48 \[0.21‐0.71\]    0.45 \[0.23‐0.74\]
  Eczema, no. (%)                                                             12/28 (43)            11/29 (38)
  Atopic eczema, no. (%)                                                      7 (24)                4/29 (14)
  Total IgE, kU/L (n=57)                                                      22 \[8.8‐41\]         13 \[7.3‐48\]
  Maternal asthma, no. (%)                                                    4 (14)                5 (17)
  Paternal asthma, no. (%)                                                    1 (3)                 2 (7)
  Maternal allergic rhinitis, no. (%)                                         12 (41)               12 (40)
  Paternal allergic rhinitis, no. (%)                                         10 (35)               10 (33)
  Maternal smoking, no. (%)                                                   5 (17)                4 (13)
  Paternal smoking, no. (%)                                                   12 (41)               11 (37)
  Pet ownership, no. (n=58; %)                                                9 (31)                8 (27
  Total 25(OH)D, nmol/L (n=57)                                                83 (27)               87 (20)
  25(OH)D2, nmol/L (n=57)                                                     26 (25)               25 (2)
  25(OH)D3, nmol/L (n=57)                                                     57 (32)               62 (25)
  Rhinovirus genome load, copies/mL                                           5800 \[130‐47 000\]   3000 \[22‐9700\]
  Coinfection, no. (%)                                                        9 (31)                11 (37)
  RSV, no. (%)                                                                4 (14)                4 (13
  Bocavirus, no. (%)                                                          3 (10)                3 (10
  Enterovirus, no. (%)                                                        2 (7)                 2 (7)
  Influenza virus, no. (%)                                                    0 (0)                 1 (3)
  Coronavirus, no. (%)                                                        1 (3)                 0 (0)
  Adenovirus, no. (%)                                                         1 (3)                 1 (3)
  Metapneumovirus, no. (%)                                                    1 (3)                 2 (7)
  Parainfluenza virus, no. (%)                                                1 (3)                 4 (13)
  Duration of breast feeding, months (n=48)                                   6.0 \[4.0‐9.0\]       5.0 \[2.0‐8.0\]
  Delay in starting the study drug after presentation for acute care, hours   45 \[35‐48\]          52 \[42‐74\]

B‐eos, blood eosinophil count; IgE, immunoglobulin E; RSV, respiratory syncytial virus; 25(OH)D, 25‐hydroxyvitamin D.

Data are expressed as mean (standard deviation) when normally distributed and median \[interquartile range\] when not normally distributed, or number (%) unless otherwise noted.

No significant differences were found between the groups when analyzed using *t* test, Mann‐Whitney *U* test, chi‐square test or Fisher exact test (counts \<5) when appropriate.
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3.2. Patient characteristics {#pai12749-sec-0013}
----------------------------

At study entry, the mean age of the 59 patients was 13 months (standard deviation \[SD\] 6 months), 18 (31%) were sensitized, and 23 (39%) had eczema (Table [1](#pai12749-tbl-0001){ref-type="table"}). Twenty children (34%) had at least two viruses detected in their airways. Rhinovirus genome load varied across patients, with a median of 4300 copies/mL (interquartile range \[IQR\] 79‐16 000); 23 (39%) of the patients had a rhinovirus genome load level \>7000 copies/mL (Table [2](#pai12749-tbl-0002){ref-type="table"}). Median delay in starting the study drug was 45 hours (IQR: 41‐71). The treatment groups did not differ in any patient characteristics shown in Table [1](#pai12749-tbl-0001){ref-type="table"} and Table [S2](#pai12749-sup-0001){ref-type="supplementary-material"}. In the prednisolone group 22 (76%) children and in the placebo group 22 (73%) of the children received at least one OCS course during the follow‐up.

###### 

Interaction analysis of the time to initiation of asthma control therapy, according to the study drug and different cutoffs of rhinovirus genome loads

  Cutoff for rhinovirus genome load/mL   No. (%) of patients with rhinovirus genome load \>cutoff   *P‐*value for interaction   HR (95% CI) for ≤cutoff value, prednisolone vs placebo   HR (95% CI) for \>cutoff value, prednisolone vs placebo
  -------------------------------------- ---------------------------------------------------------- --------------------------- -------------------------------------------------------- ---------------------------------------------------------
  3000                                   31/59 (55)                                                 .87                         1.79 (.65, 4.94)                                         0.60 (.27, 1.31)
  **5000**                               28/59 (48)                                                 **.04**                     **1.68 (.68, 4.14)**                                     **0.46 (.13, 1.12)**
  **7000**                               23/59 (39)                                                 **.04**                     **1.38 (.58, 3.25)**                                     **0.38 (.14, 1.01)**
  **9000**                               21/59 (36)                                                 **.02**                     **1.39 (.61, 3.15)**                                     **0.33 (.12, .95)**
  11 000                                 19/59 (32)                                                 .06                         1.23 (.56, 2.72)                                         0.36 (.12, 1.11)

HR, hazard ratio; CI, confidence interval. The statistically significant cut‐off values are marked in bold.
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3.3. Effectiveness of prednisolone {#pai12749-sec-0014}
----------------------------------

Different cutoff levels for rhinovirus genome load was tested, and three different levels were noticed statistically significant (Table [2](#pai12749-tbl-0002){ref-type="table"}). As the differences in final results did not differ significantly depending on the cutoff (data not shown), the same level with the earlier report was used.[9](#pai12749-bib-0009){ref-type="ref"} Asthma control medication was initiated in 40 of 59 (68%) children during the follow‐up, in 20 of 29 (69%) in prednisolone group, and in 20 of 30 (67%) in placebo group. In 27 (68%) children, the diagnosis was based on ≥4 wheezing episodes in addition to risk factors, in seven children (18%) on prolonged symptoms and requiring symptomatic treatment, and in 23 (23%) children on exacerbations requiring systemic corticosteroids.[10](#pai12749-bib-0010){ref-type="ref"} In five children, asthma control medication was started after the third acute wheezing episode.[11](#pai12749-bib-0011){ref-type="ref"} Overall, prednisolone did not affect the time to initiation of asthma control medication when compared to placebo (*P=*.99; Figure [2](#pai12749-fig-0002){ref-type="fig"}). However, the level of rhinovirus genome load at study entry modified the effect of prednisolone in terms of the time to initiation of asthma control medication (rhinovirus load x study drug interaction, *P*=.04, Figure [3](#pai12749-fig-0003){ref-type="fig"}). In children with a rhinovirus genome load of \>7000 copies/mL, the risk for initiation of asthma control medication was lower in the prednisolone group (n=14) compared to the placebo group (n=9; hazard ratio \[HR\] 0.38; 95% confidence interval \[CI\] 0.14‐1.01, *P*=.05, Figure [3](#pai12749-fig-0003){ref-type="fig"}). The asthma control medication was exclusively started to all placebo‐treated children with high rhinovirus load within the subsequent 14 months after the first wheezing episode (Figure [3](#pai12749-fig-0003){ref-type="fig"}). Median age of the children at the time of the initiation of asthma medication was 16 months (IQR: 9‐22 months). In children with a rhinovirus genome load of ≤7000 copies/mL, no differences were found between the prednisolone (n=15) and placebo groups (n=21; HR: 1.4, 95% CI: 0.58‐3.2, *P*=.46, Figure [3](#pai12749-fig-0003){ref-type="fig"}). No clinically significant adverse events were reported during the acute phase.

![The time to initiation of asthma control medication in children randomized to receive prednisolone or placebo for the first rhinovirus‐induced wheezing episode. No difference was found in overall analysis](PAI-28-557-g002){#pai12749-fig-0002}

![The time to initiation of asthma control medication in children randomized to receive prednisolone or placebo for the first rhinovirus‐induced wheezing episode. Data are represented according to the rhinovirus genome load. Children with a rhinovirus genome load of \>7000 copies/mL had longer time to initiation of asthma control medication in prednisolone group when compared with the placebo group. In the placebo group, asthma medication was initiated to all children with high rhinovirus genome load (n=9) during the 14 mo after the first wheezing episode](PAI-28-557-g003){#pai12749-fig-0003}

4. DISCUSSION {#pai12749-sec-0015}
=============

This is the first randomized placebo‐controlled trial to investigate the effect of OCS treatment until preschool age in carefully characterized young children suffering from their first acute rhinovirus‐induced wheezing episode. We had three main findings: First, OCS was not found to be effective overall when regarding the time to initiation of asthma control medication. Second, in the placebo group, asthma risk was high: regular asthma control medication was initiated to all children with high rhinovirus genome load during the subsequent 14 months after the first acute rhinovirus‐induced wheezing episode. Third, short course of prednisolone decreased the risk of asthma control medication in children with the first severe wheezing episode caused by high rhinovirus genome load. All of these findings are in line with previous data on the increased asthma risk associated with early rhinovirus‐induced wheezing.[6](#pai12749-bib-0006){ref-type="ref"}, [7](#pai12749-bib-0007){ref-type="ref"}, [8](#pai12749-bib-0008){ref-type="ref"}

Probable explanation for the association between rhinovirus infection and risk of asthma may be that pre‐existing airway inflammation in asthma‐prone children predisposes to rhinovirus infection.[15](#pai12749-bib-0015){ref-type="ref"} Moreover, high rhinovirus genome load has been associated with more severe airway inflammation.[16](#pai12749-bib-0016){ref-type="ref"}, [17](#pai12749-bib-0017){ref-type="ref"}, [18](#pai12749-bib-0018){ref-type="ref"}, [19](#pai12749-bib-0019){ref-type="ref"} In asthma‐prone patients, interferon responses can be deficient, thus increasing virus replication and promoting type 2 T‐cell responses in respiratory epithelial cells.[20](#pai12749-bib-0020){ref-type="ref"}, [21](#pai12749-bib-0021){ref-type="ref"} Moreover, rhinovirus infection may further intensify the inflammation by increasing the expression of eotaxin and interleukins 4 and 13, as well as by stimulating the immigration of eosinophils, macrophages, and neutrophils.[22](#pai12749-bib-0022){ref-type="ref"} Our placebo group finding of an exceptionally high risk for initiating regular asthma control medication in children with high rhinovirus genome load is consistent with these earlier findings. Nevertheless, we were surprised by the speed of asthma progression in these children.

Clinically, OCS treatment is recommended for asthma exacerbations in children, but effectiveness of OCS for the secondary prevention of asthma has not been confirmed in overall analysis of RCTs concerning children suffering from early wheezing episode.[1](#pai12749-bib-0001){ref-type="ref"}, [4](#pai12749-bib-0004){ref-type="ref"} In our earlier post hoc analysis of the Vinku study, the children with the first rhinovirus‐induced wheezing episode and/or eczema benefitted from prednisolone treatment in terms of lower risk for recurrence of wheezing in 7‐year follow‐up.[8](#pai12749-bib-0008){ref-type="ref"} Unfortunately, quantitative PCR was not used in this earlier study. By contrast, the RCT of Vinku2 did quantify virus genomic load; in an earlier analysis, we report that prednisolone treatment reduced the recurrence of wheezing in a group of children with a rhinovirus genome load of \>7000 copies/mL in a 12‐month follow‐up.[9](#pai12749-bib-0009){ref-type="ref"} Our current 4‐year results are in line with these previous findings and support the view that the risk of asthma can be reduced when high‐risk children are identified early and treated with OCS. OCS is likely to downregulate asthma‐associated inflammatory pathways by decreasing the transcription of many inflammatory genes and/or their transcription factors and increasing the expression of various anti‐inflammatory genes.[4](#pai12749-bib-0004){ref-type="ref"}, [23](#pai12749-bib-0023){ref-type="ref"} Furthermore, starting the acute care early may be important, as rhinovirus load peaks early in infection.[24](#pai12749-bib-0024){ref-type="ref"}

It is important to concentrate on finding the phenotype of young wheezing children that could most likely benefit from early OCS treatment. Dumas et al.[5](#pai12749-bib-0005){ref-type="ref"} used a clustering approach and identified several phenotypes for severe bronchiolitis. We speculate that those with rhinovirus etiology and/or early atopic characteristic (cluster A) would most likely benefit from early intervention trials with anti‐inflammatory medication to prevent recurrent wheezing and asthma. Our study population, especially those with high rhinovirus load, most likely represent the cluster A.

Most[9](#pai12749-bib-0009){ref-type="ref"}, [16](#pai12749-bib-0016){ref-type="ref"}, [17](#pai12749-bib-0017){ref-type="ref"}, [18](#pai12749-bib-0018){ref-type="ref"}, [19](#pai12749-bib-0019){ref-type="ref"} but not all[25](#pai12749-bib-0025){ref-type="ref"}, [26](#pai12749-bib-0026){ref-type="ref"} previous studies have shown the higher rhinovirus genome load to be associated with more severe and/or longer duration of acute lower respiratory illness. There are no previous data concerning the long‐term outcomes beyond 12 months.[9](#pai12749-bib-0009){ref-type="ref"} We used more sensitive PCR (real‐time PCR) compared to our previous study (conventional PCR and liquid hybridization),[8](#pai12749-bib-0008){ref-type="ref"} which also allows quantification of rhinovirus genome load. Here, we also used highly concentrated samples, while previous studies that did not find a relationship between viral shedding and outcomes[25](#pai12749-bib-0025){ref-type="ref"}, [26](#pai12749-bib-0026){ref-type="ref"} used nasal wash samples to estimate genome load. These differences in methodology may explain apparent discrepancies between our results and those earlier studies.

The strengths of the study include careful characterization of the patients and RCT design although blinding was opened (as planned) for the 12‐month report.[9](#pai12749-bib-0009){ref-type="ref"} However, our study has some limitations. The sample size was small but large enough to generate statistically significant results consistent with our previous studies.[8](#pai12749-bib-0008){ref-type="ref"}, [9](#pai12749-bib-0009){ref-type="ref"} Most patients were hospitalized which raises questions about the generalizability of our results to outpatients or mild wheezing illness.[27](#pai12749-bib-0027){ref-type="ref"} Rhinovirus diagnostics caused a delay in administration of the study drug which could have contributed to the lack of effectiveness of prednisolone in overall rhinovirus analysis (in addition to more sensitive PCR). In our earlier post hoc analysis with no delay in initiation of study drug and no quantitative rhinovirus detection, prednisolone was found effective in all children with rhinovirus and/or eczema.[8](#pai12749-bib-0008){ref-type="ref"}, [28](#pai12749-bib-0028){ref-type="ref"} The inflammatory profiling of T helper 1 and T helper 2 mediators in different subgroups would increase the interest of our findings but we did not do the profiling. Moreover, there were many cutoff levels of rhinovirus genome load with significant *P*‐value. In this study, we made a decision to be in line with the earlier follow‐up.[9](#pai12749-bib-0009){ref-type="ref"}

In summary, early systemic short‐course prednisolone treatment may be beneficial in reducing the risk for asthma control medication during the first 5 years in first‐time wheezing preschool children whose episode was severe and associated with high rhinovirus genome load. The results call attention to different phenotypes of bronchiolitis and early wheezing,[5](#pai12749-bib-0005){ref-type="ref"} which are likely to respond differently to different therapies. The natural course of asthma inception may be modifiable when high‐risk children are identified early, even at the time of the first wheezing episode, and targeted with an effective intervention strategy.

Supporting information
======================

###### 

 

###### 

Click here for additional data file.

We thank biomedical laboratory scientist Heidi Jokinen from Department of Clinical Virology, Turku University Hospital, Turku, Finland, for virus analyses and Tiina Peromaa from Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland, for her work as a study nurse.
